Cuts to the National Science Foundation endanger wealth of research
Look closely at your mobile phone or tablet. Touch-screen technology, speech recognition, digital sound recording and the Internet were all developed using funding from the U.S. National Science Foundation.
No matter where you live, NSF-supported research has also made your life safer. Engineering studies have reduced earthquake damage and fatalities through better building design. Improved hurricane and tornado forecasts reflect NSF investment in environmental monitoring and computer modeling of weather. NSF-supported resilience studies reduce risks and losses from wildfires.
Using NSF funding, scientists have done research that amazes, entertains and enthralls. They have drilled through mile-thick ice sheets to understand the past, visited the wreck of the Titanic and captured images of deep space.
NSF investments have made America and American science great. At least 268 Nobel laureates received NSF grants during their careers. The foundation has partnered with agencies across the government since it was created, including those dealing with national security and space exploration.
The Federal Reserve estimates that government-supported research from the NSF and other agencies has had a return on investment of 150% to 300% since 1950, meaning for every dollar U.S. taxpayers invested, they got back between $1.50 and $3.
However, that funding is now at risk.
Since January, layoffs, leadership resignations and a massive proposed reorganization have threatened the integrity and mission of the National Science Foundation. Hundreds of research grants have been terminated. The administration's proposed federal budget for fiscal year 2026 would cut NSF's funding by 55%, an unprecedented reduction that would end federal support for science research across a wide range of disciplines.
At my own geology lab, I have seen NSF grants catalyze research and the work of dozens of students who have collected data that's now used to reduce risks from earthquakes, floods, landslides, erosion, sea-level rise and melting glaciers.
I have also served on advisory committees and review panels for the NSF over the past 30 years and have seen the value the foundation produces for the American people.
American science's greatness stemmed from war
In the 1940s, with the advent of nuclear weapons, the space race and the intensification of the Cold War, American science and engineering expertise became increasingly critical for national defense. At the time, most basic and applied research was done by the military.
Vannevar Bush, an electrical engineer who oversaw military research efforts during World War II, including development of the atomic bomb, had a different idea.
He articulated an expansive scientific vision for the United States in Science: The Endless Frontier. The report was a blueprint for an American research juggernaut grounded in the expertise of university faculty, staff and graduate students.
On May 10, 1950, after five years of debate and compromise, President Harry Truman signed legislation creating the National Science Foundation and putting Bush's vision to work. Since then, the foundation has become the leading funder of basic research in the United States.
NSF's mandate, then as now, was to support basic research and spread funding for science across all 50 states. Expanding America's scientific workforce was and remains integral to American prosperity. By 1952, the foundation was awarding merit fellowships to graduate and postdoctoral scientists from every state.
There were compromises. Control of NSF rested with presidential appointees, disappointing Bush. He wanted scientists in charge to avoid political interference with the foundation's research agenda.
NSF funding matters to everyone, everywhere
Today, American tax dollars supporting science go to every state in the union.
The states with the most NSF grants awarded between 2011 and 2024 include several that voted Republican in the 2024 election -- Texas, Florida, Michigan, North Carolina and Pennsylvania -- and several that voted Democratic, including Massachusetts, New York, Virginia and Colorado.
More than 1,800 public and private institutions, scattered across all 50 states, receive NSF funding. The grants pay the salaries of staff, faculty and students, boosting local employment and supporting college towns and cities. For states with major research universities, those grants add up to hundreds of millions of dollars each year. Even states with few universities each see tens of millions of dollars for research.
As NSF grant recipients purchase lab supplies and services, those dollars support regional and national economies.
When NSF budgets are cut and grants are terminated or never awarded, the harm trickles down and communities suffer. Initial NSF funding cuts are already rippling across the country, affecting both national and local economies in red, blue and purple states alike.
An analysis of a February 2025 proposal that would cut about US$5.5 billion from National Institutes of Health grants estimated the ripple effect through college towns and supply chains would cost $6.1 billion in GDP, or total national productivity, and over 46,000 jobs.
Uncertain future for American science
America's scientific research and training enterprise has enjoyed bipartisan support for decades. Yet, as NSF celebrates its 75th birthday, the future of American science is in doubt. Funding is increasingly uncertain, and politics is driving decisions, as Bush feared 80 years ago.
A list of grants terminated by the Trump administration, collected both from government websites and scientists themselves, shows that by early May 2025, NSF had stopped funding more than 1,400 existing grants, totaling over a billion dollars of support for research, research training and education.
Most terminated grants focused on education -- the core of science, technology and engineering workforce development critical for supplying highly skilled workers to American companies. For example, NSF provided 1,000 fewer graduate student fellowships in 2025 than in the decade before -- a 50% drop in support for America's best science students.
American scientists are responding to NSF's downsizing in diverse ways. Some are pushing back by challenging grant terminations. Others are preparing to leave science or academia. Some are likely to move abroad, taking offers from other nations to recruit American experts. Science organizations and six prior heads of the NSF are calling on Congress to step up and maintain funding for science research and workforce development.
If these losses continue, the next generation of American scientists will be fewer in number and less well-prepared to address the needs of a population facing the threat of more extreme weather, future pandemics and the limits to growth imposed by finite natural resources and other planetary limits.
Investing in science and engineering is an investment in America. Diminishing NSF and the science it supports will hurt the American economy and the lives of all Americans.
Paul Bierman is a professor of natural resources and environmental science at the University of Vermont. This article is republished from The Conversation under a Creative Commons license. Read the original article. The views and opinions expressed in this article are solely those of the author.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
an hour ago
- New York Post
Menopause drug might prevent breast cancer and treat hot flashes, research finds
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, 'significantly reduced' breast tissue cell growth, which is a major indicator of cancer progression. Advertisement A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. Advertisement 'The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo,' Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. 5 New research from Northwestern University found that the drug Duavee 'significantly reduced' breast tissue cell growth, a major indicator of cancer progression. Marko Geber – Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. 'This would be expected, as the drug is FDA-approved to treat hot flashes.' Advertisement Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 5 The women in the study were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Gorodenkoff – 5 Those who took the drug reported fewer hot flashes during the study. fizkes – The findings are preliminary and have not yet been published in a medical journal. Advertisement 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced 'high-risk lesions' — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. 'These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options,' the release stated. Study limitations The researchers said they are 'encouraged' by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. 'Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure,' Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. 5 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' Dr. Swati Kulkarni said. sarayutsridee – Advertisement 'While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk,' he told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, 'which does not always predict reduced recurrence of breast cancer.' 'This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer,' he noted. 5 According to Kulkarni,'larger studies with several years of follow-up are needed' to confirm that the drug prevents breast cancer. Science RF – Advertisement 'Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention.' Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. 'Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,' she added.


Axios
6 hours ago
- Axios
The great poaching: America's brain drain begins
The Trump administration's spending cuts and restrictions on foreign students are triggering a brain drain — and American scientists are panicking. Why it matters: U.S. researchers' fears are coming true. America's science pipeline is drying up, and countries like China are seizing the opportunity to surge ahead. 'This is such a race for being the science powerhouse that you never fully recover,' says Marcia McNutt, president of the National Academy of Sciences. 'You might accelerate back up to 60, but you can't make up for those years when you were at a standstill while the competition was racing ahead.' Driving the news: The National Science Foundation, which funds much of America's fundamental science research, is already doling out grants at its slowest pace in 35 years, The New York Times reports. More cuts to science could come with the "big, beautiful bill." Universities are also watching with bated breath as the administration tries to limit the number of foreign students studying in the U.S.. Harvard is pushing back, but could face a total ban on recruiting internationally. The Trump administration says it will " aggressively revoke" visas for Chinese students studying in "critical fields." By the numbers: While American universities are rescinding offers to incoming PhD students, other countries are recruiting heavily from U.S. labs. The journal Nature analyzed data from its jobs platform to track where scientists are looking for work. In the first few months of the Trump administration, there were jumps in the the number of U.S. applicants looking for jobs in Canada (+41%), Europe (+32%), China (+20%) and other Asian countries (+39%), compared to the same period in 2024. U.S. jobs saw fewer applications from candidates in Canada (–13%) and Europe (–41%). Case in point: France's Aix-Marseille University, which made headlines for earmarking millions of dollars for U.S. scientists, closed its application window after receiving a flood of apps. After American Nobel laureate Ardem Patapoutian's federal grant was frozen, he got an email from China offering 20 years of funding if he relocates his lab, The New York Times' Kate Zernike writes. He declined. 'This is a once-in-a-century brain gain opportunity,' the Australian Strategic Policy Institute wrote in a brief. The other side: The White House argues that its changes to the system will usher in a golden age of science and rebuild public trust. President Trump has also suggested that spots freed up by rejecting international students could be filled by American applicants. But professors say this isn't entirely realistic. "In hard sciences, in astronomy and physics and computer science, for example, there's no way you would fill that hole with local applicants of comparable quality," says Chris Impey, an astronomer at the University of Arizona. What to watch: 'The optimistic part of all of us thinks science is strong enough to outlast one administration, and for a while I thought that, but the hit to young people is at the center of the whole enterprise,' Impey says. 'It's like pulling the rug out from under the whole thing." It's not just brain drain of existing talent, he says. Students who are in high school and college now and thinking about a career in research might reconsider. "There's plenty of things smart kids can do. They don't have to go into science." At the same time, McNutt says she tells students: "If you went into graduate school in the fall of this year, by the time you get your PhD, this madness may be over. You come out with your new PhD ready to fill the gap."

Washington Post
8 hours ago
- Washington Post
White House security staff warned Musk's Starlink is a security risk
Elon Musk's team at the U.S. DOGE Service and allies in the Trump administration ignored White House communications experts worried about potential security breaches when they installed Musk's Starlink internet service in the complex this year, three people familiar with the matter told The Washington Post. The people, who spoke on the condition of anonymity to discuss sensitive issues, said those who were managing White House communications systems were not informed in advance when DOGE representatives went to the roof of the adjacent Eisenhower Executive Office Building in February to install a terminal connecting users in the complex to Starlink satellites, which are owned by Musk's private SpaceX rocket company.